News | November 11, 2021
Metropolis Healthcare PAT at Rs 58.26 cr in Q2FY22
Metropolis Healthcare has reported consolidated financial results for the period ended September 30, 2021
Metropolis Healthcare has reported consolidated financial results for the period ended September 30, 2021
The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Thermo Fisher Scientific expands diagnostics portfolio to support full qPCR assay development and testing workflow
The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.
The Board of Directors of Aurobindo Pharma have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Subscribe To Our Newsletter & Stay Updated
